Clinical trial landscape for pneumonia: Evolving agents against bacterial pathogens
Abstract
OBJECTIVE: Pneumonia remains a critical global health challenge, with antimicrobial resistance fundamentally reshaping therapeutic paradigms. This study aimed to characterize global trends in pneumonia-related clinical trials and assess the pipeline response to escalating antimicrobial resistance challenges. METHODS: We conducted comprehensive analysis using the INFORMA Database, searching MeSH terms 'Community-acquired pneumonia' and 'Hospital-acquired pneumonia' while restricting inclusion to bacterial infections. Interventional clinical trials investigating therapeutic agents for bacterial pneumonia were included. Data collection encompassed trial status, primary drugs, mechanisms of action, patient demographics, and completion dates. Statistical analyses included Cochran-Armitage trend tests for temporal patterns, and Chi-square goodness of fit test for age-stratified analyses. RESULTS: A total of 2,448 pneumonia-related clinical trials were identified across 113 countries from 1991 to 2024. Phase I trials demonstrated pronounced acceleration, increasing from 3.00 trials per year (1991-2000) to 14.82 trials per year (2020-2024). Five therapeutic mechanisms dominated research: cell wall synthesis inhibitors (24.5%), ribosomal subunit inhibitors (13.5%), DNA topoisomerase inhibitors (12.8%), beta-lactamase inhibitors (9.3%), and cell membrane-related mechanisms (7.9%). Agestratified analysis revealed significant disparities, with elderly-specific trials comprising only…
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Quality evaluation and in vitro interaction studies between levofloxacin 250mg and diclofenac sodium 50mg tablets
- Molecular Epidemiology of mcr-1 -Positive Polymyxin B-Resistant Escherichia coli Producing Extended-Spectrum β-Lactamase (ESBL) in a Tertiary Hospital in Shandong, China
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.